ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
Oric Pharmaceuticals (NASDAQ:ORIC) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.